Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Recombinant production

Since Ag is positive and is negative, Q is larger for the p state than for the a state. Radical pairs in the p nuclear spin state will experience a faster intersystem crossing rate than those in the a state with the result that more RPs in the p nuclear spin state will become triplets. The end result is that the scavenging product, which is fonned primarily from triplet RPs, will have an excess of spins in the p state while the recombination product, which is fonned from singlet RPs, will have an excess of a nuclear spin states. [Pg.1598]

Figure Bl.16.8. Example of CIDNP multiplet effect for a syimnetric radical pair with two hyperfme interactions on each radical. Part A is the radical pair. Part B shows the spin levels with relative Q values indicated on each level. Part C shows the spm levels with relative populations indicated by the thickness of each level and the schematic NMR spectrum of the recombination product. Figure Bl.16.8. Example of CIDNP multiplet effect for a syimnetric radical pair with two hyperfme interactions on each radical. Part A is the radical pair. Part B shows the spin levels with relative Q values indicated on each level. Part C shows the spm levels with relative populations indicated by the thickness of each level and the schematic NMR spectrum of the recombination product.
The radical cation of 1 (T ) is produced by a photo-induced electron transfer reaction with an excited electron acceptor, chloranil. The major product observed in the CIDNP spectrum is the regenerated electron donor, 1. The parameters for Kaptein s net effect rule in this case are that the RP is from a triplet precursor (p. is +), the recombination product is that which is under consideration (e is +) and Ag is negative. This leaves the sign of the hyperfine coupling constant as the only unknown in the expression for the polarization phase. Roth et aJ [10] used the phase and intensity of each signal to detemiine the relative signs and magnitudes of the... [Pg.1601]

Recovery nd Purifica.tion. The production of EH Lilly s human insulin requires 31 principal processing steps of which 27 are associated with product recovery and purification (13). The production process for human insulin, based on a fermentation which yields proinsulin, provides an instmctive case study on the range of unit operations which must be considered in the recovery and purification of a recombinant product from a bacterial fermentation. Whereas the exact sequence has not been pubUshed, the principle steps in the purification scheme are outlined in Figure la. [Pg.43]

H. Y. Aboul-Enein, in S. Ahuja, ed.. Chromatography of Pharmaceuticals Natural, Synthetic, and Recombinant Products, American Chemical Society, Washington, D.C., 1992, pp. 111-120. [Pg.264]

Escherichia coli. The genetics of this gram-negative bacterium are very well known. For this reason, many of the first efforts to produce recombinant products from this microorganism were successful. However, because of the importance of the other criteria Hsted above, many efforts failed. E. co/i is only used to produce the milk-clotting mammalian protease chymosin [9001-98-3] (rennin). [Pg.286]

It is believed that the recombination product is liable (due to the increased mobility of the hydrogen atom following the carbon atom in j3-position relative to the C—O—C bond) to isomerization and decomposition along the ester bond ... [Pg.89]

The hydride phase may be present in a catalyst as a result of the method of its preparation (e.g. hydrogen pretreatment), or it may be formed during the course of a given reaction, when a metal catalyst is absorbing hydrogen (substrate—e.g. in H atom recombination product—e.g. in HCOOH decomposition). The spontaneous in situ transformation of a metal catalyst (at least in its superficial layer) into a hydride phase is to be expected particularly when the thermodynamic conditions are favorable. [Pg.286]

Cellular cytokines (interferons, G-CSF) and immune response modifiers originally produced from human cells, most often leukocytes, have now been replaced with recombinant products with well-defined structure/function. Futuristic advances in experimental hematology portend development of human blood cells produced from the hemopoetic stem cells. Yet for the foreseeable future, homologous blood donated by healthy, altruistic voluntary blood donors remains the principal source of safe and adequate supply of blood and blood products for transfusion therapy. [Pg.265]

G-CSF (recombinant products molgramostim, sar-gramostim) is locally active and remains at the site of infection to localize and activate neutrophils [4]. Like G-CSF, GM-CSF stimulates the proliferation,... [Pg.579]

SCF (recombinant product ancestim) is an early-acting hematopoietic growth factor that stimulates the proliferation of primitive hematopoietic and nonhema-topoietic cells [7]. In vitro, SCF has minimal effect on hematopoietic and nonhematopoietic progenitor cells, but it synergistically increases the activity of other hematopoietic growth factors, such as G-CSF, GM-CSF, and EPO. SCF stimulates the generation of dendritic cells in vitro and mast cells in vivo. [Pg.580]

Thrombopoietic factors (no recombinant TPO product in clinical use at this time IL-11 [recombinant product oprelvekin] has marketing approval) stimulate the production of megakaryocyte precursors, megakaryocytes, and platelets [8]. Interleukin-11 has many effects on multiple tissues, and can interact with IL-3, TPO, and SCF. AMG 531, a recombinant peptibody in that binds to the thrombopoetin receptor Mpl and stimulates the production of platelets, is in phase 1 and 2 studies and has been shown to safely increase platelet counts in patients with immune thrombocytopenic purpura [9]. [Pg.581]

A second approach has been to use an unsymmetrical initiator which allows the two radicals of interest to be generated simultaneously in equimolar amounts.175 In this case, analysis of the cage recombination products provides information on cross termination uncomplicated by homotermination. Analysis of products of the encounter reaction can also give information on the relative importance of cross and homotermination. However, copolymerization of unsaturated products can cause severe analytical problems. [Pg.371]

The theory and application of this fluorescence method have been discussed in detail by LePecq and others (3,8). The assay requires that there is sufficient ionic strength to minimize ionic binding (e.g., O.IM sodium chloride), that the pH is 4-10, that no heavy metals are present, that the fluorescence is not enhanced on binding to other excipients (e.g., proteins) and that at least portions of the nucleic acids are not complexed. These requirements can usually he met when dealing with recombinant products in some cases the samples must he manipulated to create the appropriate conditions. In the intercalative method of dye binding, proteins rarely interfere with the assay, and procedures have been developed to remove the few interferences they may cause (e.g., the use of heparin or enzymatic digestion of the protein 9). [Pg.46]

In addition to measuring total recombination coefficients, experimentalists seek to determine absolute or relative yields of specific recombination products by emission spectroscopy, laser induced fluorescence, and optical absorption. In most such measurements, the products suffer many collisions between their creation and detection and nothing can be deduced about their initial translational energies. Limited, but important, information on the kinetic energies of the nascent products can be obtained by examination of the widths of emitted spectral lines and by... [Pg.51]

Recombination reactions of this type have been reviewed by Adams18 and by Johnsen and Mitchell19 (this volume) from the experimental viewpoint and by Bates from a theoretical viewpoint.20 The recombination products will be critically dependent on the isomeric form of ABCD+, i.e. the weakly bonded form, AB+ CD, is more likely to produce AB + CD, whereas other products will be more likely for... [Pg.86]


See other pages where Recombinant production is mentioned: [Pg.1596]    [Pg.1597]    [Pg.1598]    [Pg.1598]    [Pg.1600]    [Pg.1600]    [Pg.50]    [Pg.54]    [Pg.54]    [Pg.454]    [Pg.229]    [Pg.286]    [Pg.286]    [Pg.834]    [Pg.361]    [Pg.579]    [Pg.580]    [Pg.85]    [Pg.46]    [Pg.324]    [Pg.697]    [Pg.127]    [Pg.409]    [Pg.21]    [Pg.52]    [Pg.58]    [Pg.61]    [Pg.64]    [Pg.77]    [Pg.87]    [Pg.331]    [Pg.108]    [Pg.165]    [Pg.252]    [Pg.264]   
See also in sourсe #XX -- [ Pg.152 ]




SEARCH



Application for the Production of Recombinant Proteins

Biotechnology products recombinant

Blood products recombinant coagulation factors

Cage recombination product

Challenges and Solutions for the Production of Recombinant Proteins

Cofactor Engineering for Xylitol Production in Recombinant Saccharomyces cerevisiae

Considerations for Recombinant Antibody Production

Marketed recombinant proteins biological product

Novel Sprouting Technology for Recombinant Protein Production

Peptide recombinant production

Production of Recombinant Proteins in D. discoideum

Production of Recombinant Proteins in Plants

Production of human insulin by recombinant DNA technology

Protein recombinant production

Recombinant DNA production

Recombinant DNA products

Recombinant Drug Products

Recombinant antibody production

Recombinant antibody production during

Recombinant antibody production monitoring galactosylation levels

Recombinant blood products and therapeutic enzymes

Recombinant drugs production systems

Recombinant production of self-assembling proteins

Recombinant proteins large-scale production

Recombinant proteins product content

Recombinant proteins transgenic production

Recombinant virus products

Recombination products

Recombination products

Scale Production of Recombinant Proteins

Vectors recombinant virus production

© 2024 chempedia.info